Summary

Global Antisense and RNAi therapeutics Market is valued approximately at USD 3.69 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 18.72% over the forecast period 2023-2030. Antisense and RNA interference (RNAi) therapeutics represent innovative approaches in the field of molecular medicine, aiming to target specific genes implicated in diseases at the level of RNA. Antisense therapy involves the use of synthetic nucleic acid molecules to bind complementary mRNA sequences, thereby inhibiting gene expression or altering splicing patterns. This approach can modulate protein production, making it potentially useful for treating various conditions, including genetic disorders and viral infections. On the other hand, RNAi therapeutics harness the natural cellular machinery to degrade specific mRNA molecules, effectively silencing the expression of target genes. The Antisense and RNAi therapeutics market is expanding because of factors such as increasing incidence of genetic disorders, growing pipeline of antisense and RNAi drugs and increasing investment and funding for therapeutics development.

Antisense technology, known for its efficacy in manipulating gene expression, has emerged as a successful treatment option for various medical conditions. Companies are seizing the opportunities presented by antisense and RNAi technologies, driving advancements in this domain. For instance, in January 2023, Agilent Technologies Inc. committed a significant investment of USD 725 million to bolster the manufacturing capacity of therapeutic nucleic acids. This expanded capability is poised to enable the company to meet the robust demand for small interfering RNA (siRNA) and antisense molecules. Similarly, In March 2023, Switch Therapeutics, a burgeoning biotechnology firm, unveiled its debut after securing USD 52 million in financing. Leveraging its innovative technology called Conditionally Activated siRNA (CASi), the company has crafted a cell-selective gene knockdown platform poised to propel the evolution of the next generation of RNA interference (RNAi) therapies. These advancements signal a notable surge in innovation within the market. In addition, rising development of personalized medicine, increased collaboration and partnerships are some factors creating new opportunities to the market growth. However, the high cost of Antisense and RNAi therapeutics stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Antisense and RNAi therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share. The presence of advanced antisense and RNAi therapeutics along with presence of sophisticated healthcare infrastructure in the region. This robust infrastructure has facilitated an upswing in the early screening of rare diseases, consequently fueling an increased demand for antisense and RNAi therapeutics. Europe is expected to grow at the fastest rate during the forecast period. The burgeoning presence of multiple enterprises dedicated to antisense and RNAi therapeutics is poised to propel regional growth throughout the forecast period. These entities are actively engaging in various endeavors to broaden their product spectrum and avenues for business. For example, in March 2023, SciNeuro Pharmaceuticals, a U.S.-based firm, entered into a partnership with Secarna Pharmaceuticals GmbH & Co. KG, headquartered in Europe. This collaboration aims to develop innovative antisense oligonucleotide (ASO) therapies targeting pivotal disease mechanisms in the Central Nervous System. Consequently, the escalating attention from industry stakeholders in different geographical spheres towards the European market is projected to invigorate regional expansion in the foreseeable future.

Major market player included in this report are:
GSK plc
Olix Pharmaceuticals, Inc.
Sanofi S.A
Alnylam Pharmaceuticals, Inc.
Arbutus Biopharma
Benitec Biopharma Inc.
Silence Therapeutics
Ionis Pharmaceuticals, Inc
Sarepta Therapeutics
Percheron Therapeutics Limited

Recent Developments in the Market:
 In August 2023, Sirnaomics Ltd disclosed the successful conclusion of the phase I clinical study for STP707, an RNAi therapeutic designed to address various solid tumors.
 In July 2023, Alnylam Pharmaceuticals, Inc. forged a partnership with Roche to collaborate on the development and commercialization of zilebesiran, an investigational RNA interference (RNAi) therapeutic aimed at managing hypertension.

Global Antisense and RNAi therapeutics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered – Technology, Application, Route of Administration, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
 Customization Scope - Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Technology:
RNA Interference
Antisense RNA

By Application:
Genetic Disease
Cancer
Infectious Disease
Neurodegenerative Disorders
Cardiometabolic & Renal Disorders
Ocular Disorders
Respiratory Disorders
Skin Disorders
By Route of Administration:
Intravenous Injections
Intrathecal Injections
Subcutaneous Injections
Other Delivery Methods


By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
1.2.1. Antisense and RNAi therapeutics Market, by region, 2020-2030 (USD Billion)
1.2.2. Antisense and RNAi therapeutics Market, by Technology, 2020-2030 (USD Billion)
1.2.3. Antisense and RNAi therapeutics Market, by Application, 2020-2030 (USD Billion)
1.2.4. Antisense and RNAi therapeutics Market, by Route of Administration, 2020-2030 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Antisense and RNAi therapeutics Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Antisense and RNAi therapeutics Market Dynamics
3.1. Antisense and RNAi therapeutics Market Impact Analysis (2020-2030)
3.1.1. Market Drivers
3.1.1.1. Increasing incidences of genetic disorders
3.1.1.2. Growing pipeline of antisense and RNAi drugs
3.1.1.3. Increasing investment and funding for therapeutics development
3.1.2. Market Challenges
3.1.2.1. High Cost of Antisense and RNAi therapeutics
3.1.3. Market Opportunities
3.1.3.1. Rising development of personalized medicine
3.1.3.2. Increased collaboration and partnerships
Chapter 4. Global Antisense and RNAi therapeutics Market: Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Impact Analysis
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economic
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. COVID-19 Impact Analysis
4.7. Disruptive Trends
4.8. Industry Expert Perspective
4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Antisense and RNAi therapeutics Market, by Technology
5.1. Market Snapshot
5.2. Global Antisense and RNAi therapeutics Market by Technology, Performance - Potential Analysis
5.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
5.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
5.4.1. RNA Interference
5.4.2. Antisense RNA
Chapter 6. Global Antisense and RNAi therapeutics Market, by Application
6.1. Market Snapshot
6.2. Global Antisense and RNAi therapeutics Market by Application, Performance - Potential Analysis
6.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
6.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
6.4.1. Genetic Disease
6.4.2. Cancer
6.4.3. Infectious Disease
6.4.4. Neurodegenerative Disorders
6.4.5. Cardiometabolic & Renal Disorders
6.4.6. Ocular Disorders
6.4.7. Respiratory Disorders
6.4.8. Skin Disorders
Chapter 7. Global Antisense and RNAi therapeutics Market, by Route of Administration
7.1. Market Snapshot
7.2. Global Antisense and RNAi therapeutics Market by Route of Administration, Performance - Potential Analysis
7.3. Global Antisense and RNAi therapeutics Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
7.4. Antisense and RNAi therapeutics Market, Sub Segment Analysis
7.4.1. Intravenous Injections
7.4.2. Intrathecal Injections
7.4.3. Subcutaneous Injections
7.4.4. Other Delivery Methods
Chapter 8. Global Antisense and RNAi therapeutics Market, Regional Analysis
8.1. Top Leading Countries
8.2. Top Emerging Countries
8.3. Antisense and RNAi therapeutics Market, Regional Market Snapshot
8.4. North America Antisense and RNAi therapeutics Market
8.4.1. U.S. Antisense and RNAi therapeutics Market
8.4.1.1. Technology breakdown estimates & forecasts, 2020-2030
8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
8.4.1.3. Route of Administration breakdown estimates & forecasts, 2020-2030
8.4.2. Canada Antisense and RNAi therapeutics Market
8.5. Europe Antisense and RNAi therapeutics Market Snapshot
8.5.1. U.K. Antisense and RNAi therapeutics Market
8.5.2. Germany Antisense and RNAi therapeutics Market
8.5.3. France Antisense and RNAi therapeutics Market
8.5.4. Spain Antisense and RNAi therapeutics Market
8.5.5. Italy Antisense and RNAi therapeutics Market
8.5.6. Rest of Europe Antisense and RNAi therapeutics Market
8.6. Asia-Pacific Antisense and RNAi therapeutics Market Snapshot
8.6.1. China Antisense and RNAi therapeutics Market
8.6.2. India Antisense and RNAi therapeutics Market
8.6.3. Japan Antisense and RNAi therapeutics Market
8.6.4. Australia Antisense and RNAi therapeutics Market
8.6.5. South Korea Antisense and RNAi therapeutics Market
8.6.6. Rest of Asia Pacific Antisense and RNAi therapeutics Market
8.7. Latin America Antisense and RNAi therapeutics Market Snapshot
8.7.1. Brazil Antisense and RNAi therapeutics Market
8.7.2. Mexico Antisense and RNAi therapeutics Market
8.8. Middle East & Africa Antisense and RNAi therapeutics Market
8.8.1. Saudi Arabia Antisense and RNAi therapeutics Market
8.8.2. South Africa Antisense and RNAi therapeutics Market
8.8.3. Rest of Middle East & Africa Antisense and RNAi therapeutics Market

Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Company 1
9.1.2. Company 2
9.1.3. Company 3
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. GSK plc
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Recent Developments
9.3.2. Olix Pharmaceuticals, Inc.
9.3.3. Sanofi S.A
9.3.4. Alnylam Pharmaceuticals, Inc.
9.3.5. Arbutus Biopharma
9.3.6. Benitec Biopharma Inc.
9.3.7. Silence Therapeutics
9.3.8. Ionis Pharmaceuticals, Inc
9.3.9. Sarepta Therapeutics
9.3.10. Percheron Therapeutics Limited
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption